To hear about similar clinical trials, please enter your email below

Trial Title: A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer

NCT ID: NCT05483439

Condition: Stage II-III Breast Cancer

Conditions: Official terms:
Breast Neoplasms
Cyclophosphamide
Carboplatin
Docetaxel
Trastuzumab
Epirubicin
Pertuzumab
Antibodies
Antibodies, Monoclonal

Study type: Interventional

Study phase: Phase 2

Overall status: Unknown status

Study design:

Allocation: Randomized

Intervention model: Parallel Assignment

Primary purpose: Treatment

Masking: None (Open Label)

Intervention:

Intervention type: Drug
Intervention name: cytotoxic chemotherapy (docetaxel or epirubicin or cyclophosphamide or carboplatin)
Description: Drug: cytotoxic chemotherapy (docetaxel or epirubicin or cyclophosphamide or carboplatin)
Arm group label: Immunotherapy and neoadjuvant therapy
Arm group label: neoadjuvant therapy

Intervention type: Drug
Intervention name: anti-Her2 monoclonal antibody (Trastuzumab, Pertuzumab)
Description: anti-Her2 monoclonal antibody (Trastuzumab, Pertuzumab)
Arm group label: Immunotherapy and neoadjuvant therapy
Arm group label: neoadjuvant therapy

Intervention type: Drug
Intervention name: traditional herbal medicine
Description: traditional herbal medicine
Arm group label: Immunotherapy and neoadjuvant therapy

Summary: This is a randomized, open label Phase II neoadjuvant study comparing the efficacy and safety of the combination of traditional herbal medicine for cancer immunotherapy and neoadjuvant therapy versus neoadjuvant therapy in patients with breast cancer.

Detailed description: This is a randomized, open label Phase II neoadjuvant study comparing the efficacy and safety of the combination of traditional herbal medicine for cancer immunotherapy and neoadjuvant therapy versus neoadjuvant therapy in patients with breast cancer. Patients will be randomized (1:1) to one of the two treatment arms: arm 1, combination of traditional herbal medicine for cancer immunotherapy and neoadjuvant therapy for 6 or 8 cycles; arm 2, neoadjuvant therapy 6 or 8 cycles. Patients will undergo surgery after neoadjuvant therapy. Efficacy will be assessed every 2 cycles.

Criteria for eligibility:
Criteria:
Inclusion Criteria: 1. Female patients aged ≥ 18 but ≤ 75 years; 2. Diagnosis of breast cancer meets the following criteria: Stage II-III patients who meet the 8th edition of AJCC Cancer Staging Manual and meet the indications of neoadjuvant therapy; 3. Diagnosis of breast cancer meets the following criteria: Histologically confirmed invasive breast cancer 4. KPS score≥70 5. The functional level of major organs must conform to the following requirements: Neutrophils (ANC) ≥ 1.5×10^9/L (with no use of growth factors within 14 days); Platelet count (PLT) ≥ 100×10^9/L (with no correct treatment within 7 days ); Hemoglobin (Hb) ≥ 90 g/L (with no correct treatment within 7 days ); Total bilirubin (TBIL) ≤ 1.5×upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3×ULN; Urea nitrogen and creatinine ≤ 1.5×ULN and creatinine clearance ≥ 50 mL/min (Cockcroft-Gault formula); Cardiac color Doppler ultrasound: left ventricular ejection fraction (LVEF) ≥ 50%; 12-lead electrocardiogram: QT interval ≤ 480 ms; 6. Patients who participate in the trial voluntarily, sign an informed consent, have good compliance and are willing to comply with the follow-up visit. Exclusion Criteria: 1. Previously received any anti-tumor therapy (chemotherapy, radiotherapy, molecular targeted therapy, endocrine therapy, etc.); 2. Patients who are concurrently receiving other anti-tumor therapy; 3. Bilateral breast cancer, inflammatory breast cancer, or occult breast cancer; 4. Stage IV breast cancer; 5. Intolerant to herbs or poor compliance; 6. With a history of any malignancies other than breast cancer in the past 5 years, excluding cured cervical carcinoma in situ and melanoma skin cancer; 7. Severe heart, liver, kidney and other important organ dysfunction; 8. Inability to swallow, chronic diarrhea and intestinal obstruction, and having many factors that affect drug administration and absorption; 9. Participated in clinical trials of other drugs within 4 weeks before enrollment; 10. Known history of allergy to the drug components of this regimen; History of immunodeficiency, including HIV positive, HCV, live active hepatitis B or other acquired or congenital immune deficiency diseases, or a history of organ transplantation; 11. Have used drugs that affect immune function within 1 year; 12. Once suffered from any heart disease, including: (1) arrhythmia with clinical significance, (2) myocardial infarction; (3) heart failure; (4) investigator's judgment as not suitable for participating in this trial; 13. Pregnant, lactating women, fertile women with positive baseline pregnancy test or in the entire women of reproductive age who were unwilling to use effective contraception during the trial; 14. According to the investigator's judgment, there are comorbidities (including but) that seriously endanger the patient's safety or affect the patient's ability to complete the study not limited to severe hypertension, severe diabetes, active infection, etc., which cannot be controlled by drugs); 15. A clear past history of neurological or psychiatric disorders, including epilepsy or dementia. The investigator considered the patient unsuitable for the study in any other case.

Gender: All

Minimum age: 18 Years

Maximum age: 75 Years

Healthy volunteers: No

Locations:

Facility:
Name: ShengJing ospital of China Medical University

Address:
City: Shenyang
Zip: 110022
Country: China

Status: Recruiting

Contact:
Last name: Liu Caigang

Phone: +8618940254967
Email: liucg@sj-hospital.org

Contact backup:
Last name: Niu Nan

Phone: +8618940256668
Email: niunannancy@163.com

Investigator:
Last name: Liu Caigang
Email: Principal Investigator

Facility:
Name: Shengjing Hospital Affiliated to China Medical University

Address:
City: Shenyang
Country: China

Status: Recruiting

Contact:
Last name: CaoShuo Cao, doctor

Phone: 18940254228

Start date: October 20, 2021

Completion date: July 1, 2023

Lead sponsor:
Agency: Shengjing Hospital
Agency class: Other

Source: Shengjing Hospital

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05483439

Login to your account

Did you forget your password?